Please assess the completion status of the following clinical trial:

Trial Title: Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 15-65~2. Ph-(BCR-ABL1 negative)B-ALL was diagnosed according to WHO diagnostic criteria~3. Newly diagnosed patients without prior induction therapy (except hydroxyurea and glucocorticoids ≦5 days)~4. ECOG score 0-3~5. Liver function: total bilirubin ≦ 3 times the upper limit of normal; Alanine aminotransferase ≦ 3 times upper limit of normal motion; Aspartate aminotransferase ≦ 3 times upper limit of normal motion; (except considering leukemia infiltration)~6. Renal function: endogenous creatinine clearance ≧30ml/min~7. Patients must be able to understand and willing to participate in the study and must sign the informed consent form.~Exclusion Criteria:~1. Ph+ (BCR-ABL1 positive) ALL and known ABL class Ph-Like ALL~2. T cells ALL~3. Mature B-cell leukemia/lymphoma, B-cell lymphoma, isolated extramedullary disease~4. Acute mixed-cell leukemia~5. Central nervous system leukemia~6. HIV infection~7. HBV-DNA or HCV-RNA positive~8. Patients with grade 2 or higher heart failure and other patients deemed inappropriate for inclusion by the investigator~9. Pregnant or breastfeeding patients~10. The study patient was refused enrollment

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- reduced-intensity chemotherapy followed by berintuzumab (Type: EXPERIMENTAL): Induction therapy was performed with reduced intensity chemotherapy (including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vindesine 3 mg/m2, and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. Bone marrow evaluation was performed on day 22±2, and consolidation therapy was performed after achieving bone marrow remission (CR/CRh/CRi). If CR/CRh/CRi was not achieved in the first course of induction therapy, Blinatumomab (28ug/d×14d) should be continued and bone marrow evaluation should be evaluated again.~The regimen of consolidation therapy is recommended as multidrug combination chemotherapy (including high-dose Methotrexate or Cytarabine combined with Asparaginase) or alternating with Blinatumomab (28 ug/d×28d). If Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is not performed, consolidation therapy needs at least 4 courses before 2 years maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).